Chimeric Therapeutics Limited Stock Performance
| CHMMF Stock | 0 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Chimeric Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Chimeric Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable primary indicators, Chimeric Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 22.4 M | |
| Total Cashflows From Investing Activities | -577.9 K |
Chimeric |
Chimeric Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.10 in Chimeric Therapeutics Limited on August 12, 2025 and sell it today you would earn a total of 0.00 from holding Chimeric Therapeutics Limited or generate 0.0% return on investment over 90 days. Chimeric Therapeutics Limited is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Chimeric, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Chimeric Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chimeric Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Chimeric Therapeutics Limited, and traders can use it to determine the average amount a Chimeric Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CHMMF |
Based on monthly moving average Chimeric Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chimeric Therapeutics by adding Chimeric Therapeutics to a well-diversified portfolio.
Chimeric Therapeutics Fundamentals Growth
Chimeric Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Chimeric Therapeutics, and Chimeric Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Chimeric Pink Sheet performance.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (5.57) % | |||
| Current Valuation | 56.81 K | |||
| Shares Outstanding | 437.09 M | |||
| Price To Book | 1.49 X | |||
| Price To Sales | 10.02 X | |||
| Revenue | 2.62 M | |||
| EBITDA | (14.14 M) | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (13.15 M) | |||
| Total Asset | 34.88 M | |||
About Chimeric Therapeutics Performance
By analyzing Chimeric Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Chimeric Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Chimeric Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Chimeric Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Chimeric Therapeutics performance evaluation
Checking the ongoing alerts about Chimeric Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Chimeric Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Chimeric Therapeutics generated a negative expected return over the last 90 days | |
| Chimeric Therapeutics has some characteristics of a very speculative penny stock | |
| Chimeric Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.62 M. Net Loss for the year was (15.9 M) with profit before overhead, payroll, taxes, and interest of 2.62 M. | |
| Chimeric Therapeutics generates negative cash flow from operations | |
| About 48.0% of the company shares are held by company insiders |
- Analyzing Chimeric Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Chimeric Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Chimeric Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Chimeric Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Chimeric Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Chimeric Therapeutics' pink sheet. These opinions can provide insight into Chimeric Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Chimeric Pink Sheet analysis
When running Chimeric Therapeutics' price analysis, check to measure Chimeric Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chimeric Therapeutics is operating at the current time. Most of Chimeric Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chimeric Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chimeric Therapeutics' price. Additionally, you may evaluate how the addition of Chimeric Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |